KINNATE BIOPHARMA INC (KNTE) Stock Price & Overview
NASDAQ:KNTE • US49705R1059
Current stock price
The current stock price of KNTE is 2.65 USD. Today KNTE is down by -0.38%. In the past month the price increased by 2.32%. In the past year, price decreased by -56.63%.
KNTE Key Statistics
- Market Cap
- 125.001M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -2.42
- Dividend Yield
- N/A
KNTE Stock Performance
KNTE Stock Chart
KNTE Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to KNTE. When comparing the yearly performance of all stocks, KNTE is a bad performer in the overall market: 86.11% of all stocks are doing better.
KNTE Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to KNTE. No worries on liquidiy or solvency for KNTE as it has an excellent financial health rating, but there are worries on the profitability.
KNTE Earnings
KNTE Forecast & Estimates
10 analysts have analysed KNTE and the average price target is 2.41 USD. This implies a price decrease of -9.04% is expected in the next year compared to the current price of 2.65.
KNTE Groups
Sector & Classification
KNTE Financial Highlights
Over the last trailing twelve months KNTE reported a non-GAAP Earnings per Share(EPS) of -2.42. The EPS increased by 8.68% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -64.89% | ||
| ROE | -70.7% | ||
| Debt/Equity | 0 |
KNTE Ownership
KNTE Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.49 | 380.121B | ||
| AMGN | AMGEN INC | 15.48 | 190.443B | ||
| GILD | GILEAD SCIENCES INC | 15.87 | 174.171B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.07 | 113.617B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.62 | 82.171B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 44.06 | 43.596B | ||
| INSM | INSMED INC | N/A | 35.536B | ||
| NTRA | NATERA INC | N/A | 28.801B | ||
| BIIB | BIOGEN INC | 11.43 | 26.972B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.09 | 24.995B | ||
| MRNA | MODERNA INC | N/A | 19.759B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.548B | ||
| INCY | INCYTE CORP | 12.31 | 18.767B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About KNTE
Company Profile
Kinnate Biopharma, Inc. operates as a biopharmaceutical company engaged in the research and development of Kinnate Discovery Engine that targets genomic drivers of cancer. The company is headquartered in San Diego, California and currently employs 84 full-time employees. The company went IPO on 2020-12-03. The company is focused on the discovery, design and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers. Its lead product candidate is exarafenib (KIN-2787), which is a Rapidly Accelerated Fibrosarcoma (RAF) inhibitor in development for the treatment of patients with lung cancer, melanoma and other solid tumors. Its second product candidate is KIN-3248, a Fibroblast Growth Factor Receptors (FGFR) inhibitor, designed for the treatment of patients with intrahepatic cholangiocarcinoma (ICC). KIN-3248 is designed to address clinically observed kinase domain mutations in FGFR2 and FGFR3. The company is also advancing other small molecule research programs, including a Cyclin-Dependent Kinase 12 (CDK12) inhibitor in its KIN004 program for the treatment of ovarian carcinoma (OC), triple-negative breast cancer (TNBC) and metastatic castration-resistant prostate cancer (mCRPC).
Company Info
IPO: 2020-12-03
KINNATE BIOPHARMA INC
11975 El Camino Real, Ste 101, Suite 101
San Diego CALIFORNIA 92130 US
CEO: Nima Farzan
Employees: 84
Phone: 18582994699
KINNATE BIOPHARMA INC / KNTE FAQ
What does KINNATE BIOPHARMA INC do?
Kinnate Biopharma, Inc. operates as a biopharmaceutical company engaged in the research and development of Kinnate Discovery Engine that targets genomic drivers of cancer. The company is headquartered in San Diego, California and currently employs 84 full-time employees. The company went IPO on 2020-12-03. The company is focused on the discovery, design and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers. Its lead product candidate is exarafenib (KIN-2787), which is a Rapidly Accelerated Fibrosarcoma (RAF) inhibitor in development for the treatment of patients with lung cancer, melanoma and other solid tumors. Its second product candidate is KIN-3248, a Fibroblast Growth Factor Receptors (FGFR) inhibitor, designed for the treatment of patients with intrahepatic cholangiocarcinoma (ICC). KIN-3248 is designed to address clinically observed kinase domain mutations in FGFR2 and FGFR3. The company is also advancing other small molecule research programs, including a Cyclin-Dependent Kinase 12 (CDK12) inhibitor in its KIN004 program for the treatment of ovarian carcinoma (OC), triple-negative breast cancer (TNBC) and metastatic castration-resistant prostate cancer (mCRPC).
What is the current price of KNTE stock?
The current stock price of KNTE is 2.65 USD. The price decreased by -0.38% in the last trading session.
Does KINNATE BIOPHARMA INC pay dividends?
KNTE does not pay a dividend.
What is the ChartMill rating of KINNATE BIOPHARMA INC stock?
KNTE has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the sector and industry classification for KINNATE BIOPHARMA INC?
KINNATE BIOPHARMA INC (KNTE) operates in the Health Care sector and the Biotechnology industry.
What is the employee count for KNTE stock?
KINNATE BIOPHARMA INC (KNTE) currently has 84 employees.
What is KINNATE BIOPHARMA INC worth?
KINNATE BIOPHARMA INC (KNTE) has a market capitalization of 125.00M USD. This makes KNTE a Micro Cap stock.